Bayer CEO Werner Wenning signalled that the company is set to take a break from big acquisitions after a spate of deals that have catapulted it into leading positions in healthcare and crop science.

A year after taking over German drug maker Schering, Wenning told the Financial Times that Bayer now wants to "successfully integrate (the group) before throwing ourselves into the next big transaction".